Clinical Trials Browser

Phase 2 × mirabegron × 90 days × Clear all

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms